Beam Therapeutics Inc (BEAM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.36B
Last updated: Nov 17, 2026 at 4:39 PM ET
Beam Therapeutics Inc (BEAM) Statistics
Beam Therapeutics (BEAM) has a market cap of $2.36B and an enterprise value of $2.25B. Revenue grew 163.27% over the last 12 months from the 12 months before. It kept -73.04% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 4.72% below the market cap, as cash exceeds debt.
| Market Cap | $2.36B |
|---|---|
| Enterprise Value | $2.25B |
| Latest price (Nov 17, 2026) | $20.65 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 3, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 14.7x and 2.3x. Its year-end P/S ranged from 5.9x to 104.5x from 2021 to 2025.
| P/S Ratio | 14.7x |
|---|---|
| Forward P/S | 61.4x |
| P/B Ratio | 2.3x |
Price Statistics
The stock is down 4.93% over 52 weeks and trades 16.90% below its 50-day average.
| Beta (1Y) | 2.22 |
|---|---|
| 52-Week Change | -4.93% |
| 1-Month Change | -14.63% |
| 3-Month Change | -28.96% |
| 6-Month Change | -21.57% |
| 5-Year Change | -69.33% |
| Total Return (1Y) | -4.93% |
| Total Return (3Y CAGR) | -9.07% |
| Total Return (5Y CAGR) | -25.47% |
| Return vs SPY (1Y) | -17.35% |
| Max Drawdown (1Y) | -45.54% |
| Max Drawdown (3Y) | -67.74% |
| Sharpe Ratio (1Y) | -0.08 |
| Correlation with SPY (1Y) | 0.43 |
| 50-Day Average | $24.85 |
| 200-Day Average | $27.80 |
| 52-Week Range | $20.23 to $38.26 |
| RSI (14 Days) | 34.5 |
| Average Volume (20 Days) | 2.15M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 13.00x current liabilities, and total debt is 0.11x shareholder equity.
| Current Ratio | 13.00x |
|---|---|
| Quick Ratio | 13.00x |
| Debt / Equity | 0.11x |
| Interest Coverage | 11.64x |
Returns and Efficiency
Return on invested capital is -29.73% over the last 12 months, against a 5-year average of -24.12%.
| Return on Equity (ROE) | -11.24% |
|---|---|
| Return on Assets (ROA) | -8.44% |
| Return on Invested Capital (ROIC) | -29.73% |
| ROE (5Y Average) | -31.11% |
| ROA (5Y Average) | -19.06% |
| ROIC (5Y Average) | -24.12% |
| Asset Turnover | 0.11x |
Scores
BEAM has an Altman Z-Score of 1.92, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.92 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $146.64M over the last 12 months.
| Revenue | $146.64M |
|---|---|
| Revenue Growth (YoY) | +163.27% |
| Gross Profit | $146.64M |
| Operating Income | -$392.54M |
| Pretax Income | -$107.10M |
| Net Income | -$107.10M |
| Reported EPS (TTM) | -$1.04 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 75.01% of the $1.27B in total assets.
| Cash and Equivalents | $213.27M |
|---|---|
| Total Debt | $101.85M |
| Net Cash | $111.42M |
| Net Cash Per Share | $1.06 |
| Working Capital | $985.30M |
| Shareholder Equity | $952.67M |
| Book Value Per Share | $9.10 |
| Total Assets | $1.27B |
| Total Liabilities | $316.40M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $9.59M of capital spending, operating cash flow left -$398.24M of free cash flow.
| Operating Cash Flow | -$388.65M |
|---|---|
| Capital Expenditures | $9.59M |
| Free Cash Flow | -$398.24M |
| FCF Per Share | -$3.86 |
| Depreciation and Amortization | $33.39M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -267.68%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -267.68% |
| Pretax Margin | -73.04% |
| Net Margin | -73.04% |
| FCF Margin | -271.57% |
Growth
Revenue grew 31.88% a year over 3 years.
| Revenue Growth (3Y CAGR) | +31.88% |
|---|---|
| Revenue Growth (5Y CAGR) | +466.27% |
| Book Value Per Share Growth (2Y CAGR) | -0.27% |
| Tangible Book Per Share Growth (2Y CAGR) | -0.27% |
Dividends and Yields
BEAM does not pay a dividend. Its free cash flow yield is -18.42%.
| FCF Yield | -18.42% |
|---|---|
| Buyback Yield | -0.13% |
| Shareholder Yield | -0.13% |
Peer Position
Against 7 similar companies, BEAM has the 4th highest P/S.
P/S RatioPeer median 5.2x
ROICPeer median -42.31%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 14.7x vs 5.2x median |
|---|---|
| ROIC | -29.73% vs -42.31% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +163.27% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at -52.73% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -52.73% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About BEAM
What is BEAM's market cap?
Beam Therapeutics has a market cap of $2.36B. Its enterprise value, which adds debt and subtracts cash, is $2.25B.
How many shares of BEAM are outstanding?
Beam Therapeutics has 104.70M shares outstanding. The count is up 2.07% from a year earlier.
Does BEAM pay a dividend?
No. Beam Therapeutics does not pay a dividend.
How much debt does BEAM have?
Beam Therapeutics has $101.85M of total debt and $213.27M of cash and equivalents, a net cash position of $111.42M.
BEAM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors